Kimia Biosciences Ltd
₹ 55.7
2.71%
28 Mar
4:01 p.m.
About
Incorporated in 1993, Kimia Biosciences Ltd
is in the business of Pharmaceutical products[1]
Key Points
- Market Cap ₹ 264 Cr.
- Current Price ₹ 55.7
- High / Low ₹ 58.4 / 31.3
- Stock P/E
- Book Value ₹ 0.08
- Dividend Yield 0.00 %
- ROCE -12.4 %
- ROE -81.6 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 694 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 10.9% over past five years.
- Company has a low return on equity of -16.5% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
9 | 12 | 6 | 2 | 0 | 1 | 76 | 94 | 106 | 133 | 125 | 129 | 97 | |
8 | 10 | 7 | 4 | 4 | 2 | 74 | 88 | 102 | 124 | 124 | 133 | 107 | |
Operating Profit | 1 | 2 | -0 | -2 | -3 | -1 | 2 | 6 | 4 | 8 | 1 | -5 | -10 |
OPM % | 12% | 16% | -5% | -110% | -1,779% | -56% | 3% | 6% | 4% | 6% | 0% | -4% | -10% |
0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 2 | 1 | 0 | 1 | |
Interest | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 3 | 3 | 4 | 4 | 5 |
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 3 | 3 | 3 |
Profit before tax | 0 | 1 | -1 | -2 | -4 | -1 | 2 | 4 | 1 | 6 | -5 | -12 | -18 |
Tax % | 11% | 6% | 1% | -1% | -0% | 8% | -4% | -1% | -13% | 8% | 26% | 25% | |
0 | 1 | -1 | -2 | -4 | -1 | 2 | 4 | 1 | 5 | -4 | -9 | -13 | |
EPS in Rs | 0.54 | 1.71 | -1.06 | -2.30 | -5.48 | -1.26 | 2.26 | 2.64 | 0.30 | 1.08 | -0.78 | -1.98 | -2.80 |
Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% |
Compounded Sales Growth | |
---|---|
10 Years: | 27% |
5 Years: | 11% |
3 Years: | 7% |
TTM: | -28% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -166% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 9% |
3 Years: | 14% |
1 Year: | 74% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | -3% |
3 Years: | -17% |
Last Year: | -82% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 7 | 7 | 7 | 7 | 7 | 7 | 1 | 1 | 5 | 5 | 5 | 5 | 5 |
Reserves | -6 | -5 | -6 | -7 | -11 | -12 | -2 | 2 | 9 | 14 | 10 | 1 | -4 |
Preference Capital | -0 | -0 | -0 | -0 | -0 | -0 | 1 | 1 | 0 | -0 | -0 | -0 | |
2 | 1 | 0 | 1 | 7 | 14 | 33 | 31 | 34 | 45 | 41 | 53 | 52 | |
3 | 2 | 3 | 4 | 1 | 3 | 25 | 31 | 38 | 43 | 54 | 63 | 50 | |
Total Liabilities | 7 | 6 | 6 | 5 | 4 | 12 | 58 | 65 | 86 | 107 | 109 | 121 | 102 |
3 | 4 | 4 | 3 | 3 | 7 | 13 | 16 | 18 | 28 | 35 | 34 | 33 | |
CWIP | 0 | -0 | 0 | -0 | -0 | 3 | 2 | 2 | 6 | 6 | -0 | 1 | 0 |
Investments | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | 0 | 0 | 0 | 0 | -0 |
3 | 2 | 2 | 1 | 1 | 2 | 43 | 48 | 62 | 72 | 74 | 87 | 69 | |
Total Assets | 7 | 6 | 6 | 5 | 4 | 12 | 58 | 65 | 86 | 107 | 109 | 121 | 102 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2 | 1 | 1 | 0 | -6 | -1 | -7 | -3 | 0 | 6 | 8 | -7 | |
-1 | -1 | -0 | 0 | -0 | -6 | -2 | -2 | -9 | -14 | -1 | -3 | |
-1 | -1 | -0 | -0 | 6 | 7 | 10 | 4 | 8 | 8 | -8 | 10 | |
Net Cash Flow | 0 | -0 | -0 | -0 | 0 | 0 | 0 | -0 | 0 | 0 | -0 | -0 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 80 | 41 | 22 | 56 | 173 | 20 | 141 | 113 | 128 | 115 | 88 | 87 |
Inventory Days | 75 | 50 | 319 | 615 | 59 | 83 | 92 | 89 | 146 | 183 | ||
Days Payable | 988 | 667 | 91 | 511 | 120 | 91 | 121 | 116 | 159 | 177 | ||
Cash Conversion Cycle | 80 | 41 | -891 | -560 | 401 | 124 | 80 | 105 | 100 | 88 | 76 | 93 |
Working Capital Days | -50 | -10 | -58 | -530 | -173 | -1,358 | 70 | 83 | 94 | 98 | 78 | 79 |
ROCE % | 22% | 46% | -25% | -127% | -188% | -10% | 10% | 17% | 9% | 16% | -2% | -12% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 20 Mar
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 18 Mar
- Intimation Under Regulation 30 For Written Confirmation For Active Substances Imported Into The European Union (EU) For Medicinal Products For Human Use. 4 Mar
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Feb - Dear Sir/ Madam, Pursuant to the Regulation 30 of the SEBI ( Listing Obligation and Disclosure Requirement) Regulations, 2015, please find newspaper publications of un-audited …
- Board Meeting Outcome for Board Outcome 14 Feb
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Product Profile:[1][2]
Company manufactures Active Pharmaceuticals Ingredients. It has commercialized 25+ products with 9-10 molecules under development